Real-World data on regorafenib for advanced colorectal cancer
NCT ID NCT02310477
First seen Mar 17, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study looked at how long people with advanced colorectal cancer lived after taking regorafenib, a drug given when other treatments stop working. Researchers followed 704 patients in France who received the drug through a special access program. The goal was to see real-world survival times and understand patient characteristics, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Oscar Lambret
Lille, 59020, France
Conditions
Explore the condition pages connected to this study.